within Pharmacolibrary.Drugs.ATC.G;

model G03DB01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.28,
    Cl             = 0.00010666666666666667,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.054,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.01,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G03DB01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Dydrogesterone is a synthetic progestogen, structurally related to progesterone, used in hormone replacement therapy, luteal phase support, management of various gynecological disorders such as dysmenorrhea, irregular menstrual cycles, endometriosis, and secondary amenorrhea. It is approved and in clinical use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult female volunteers after single oral administration.</p><h4>References</h4><ol><li><p>Loreti, S, Thiele, K, De Brucker, M, Olsen, C, Centelles-Lodeiro, J, Bourgain, C, Waelput, W, Tournaye, H, Griesinger, G, Raes, J, Vieira-Silva, S, Arck, P, Blockeel, C, &amp; Mackens, S (2024). Oral dydrogesterone versus micronized vaginal progesterone for luteal phase support: a double-blind crossover study investigating pharmacokinetics and impact on the endometrium. <i>Human reproduction (Oxford, England)</i> 39(2) 403–412. DOI:<a href=\"https://doi.org/10.1093/humrep/dead256\">10.1093/humrep/dead256</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38110714/\">https://pubmed.ncbi.nlm.nih.gov/38110714</a></p></li><li><p>Campagnoli, C, Abbà, C, Ambroggio, S, Lotano, MR, &amp; Peris, C (2007). Differential effects of various progestogens on metabolic risk factors for breast cancer. <i>Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology</i> 23 Suppl 1 22–31. DOI:<a href=\"https://doi.org/10.1080/09513590701585037\">10.1080/09513590701585037</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17943536/\">https://pubmed.ncbi.nlm.nih.gov/17943536</a></p></li><li><p>Neumann, K, Masuch, A, Vonthein, R, Depenbusch, M, Schultze-Mosgau, A, Eggersmann, TK, &amp; Griesinger, G (2022). Dydrogesterone and 20α-dihydrodydrogesterone plasma levels on day of embryo transfer and clinical outcome in an anovulatory programmed frozen-thawed embryo transfer cycle: a prospective cohort study. <i>Human reproduction (Oxford, England)</i> 37(6) 1183–1193. DOI:<a href=\"https://doi.org/10.1093/humrep/deac045\">10.1093/humrep/deac045</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35323905/\">https://pubmed.ncbi.nlm.nih.gov/35323905</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G03DB01;
